PERPHENAZINE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

PERPHENAZINE

Disponible desde:

AA PHARMA INC

Código ATC:

N05AB03

Designación común internacional (DCI):

PERPHENAZINE

Dosis:

8MG

formulario farmacéutico:

TABLET

Composición:

PERPHENAZINE 8MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

PHENOTHIAZINES

Resumen del producto:

Active ingredient group (AIG) number: 0106175006; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2010-05-25

Ficha técnica

PRESCRIBING INFORMATION PERPHENAZINE
PERPHENAZINE TABLETS USP
2 MG , 4 MG, 8MG, AND 16 MG
ANTIPSYCHOTIC/ANTIEMETIC
AA PHARMA INC.
DATE OF REVISION: JUNE 6, 2012
1165 CREDITSONE ROAD, UNIT #1
VAUGHAN, ONTARIO L4K 4N7
CONTROL NUMBER: 151548
1
PRESCRIBING INFORMATION
PERPHENAZINE
Perphenazine Tablets USP
2 mg, 4 mg, 8 mg and 16 mg
THERAPEUTIC CLASSIFICATION
Antipsychotic/Antiemetic
ACTIONS AND CLINICAL PHARMACOLOGY
Perphenazine is a piperazine phenothiazine derivative with
antipsychotic, antiemetic and weak sedative
activity.
Perphenazine has actions similar to those of other phenothiazine
derivatives but appears to be less
sedating and to have a weak propensity for causing hypotension or
potentiating the effects of CNS
depressants and anesthetics. However, it produces a high incidence of
extrapyramidal reactions.
Perphenazine is well absorbed from the gastrointestinal tract. Onset
of action following oral
administration is 30 to 40 minutes. Duration of action is 3 to 4
hours. Perphenazine distributes to most
body tissues with high concentrations being distributed into liver and
spleen. Perphenazine enters the
enterohepatic circulation and is excreted chiefly in the feces.
INDICATIONS AND CLINICAL USE
Perphenazine is indicated in the management of manifestations of
psychotic disorders.
It is also effective in controlling nausea and vomiting due to
stimulation of the chemoreceptor trigger
zone.
Perphenazine has not been shown effective for the management of
behavioral complications in patients
with mental retardation.
2
CONTRAINDICATIONS
Should not be administered in the presence of circulatory collapse,
altered states of consciousness or
comatose states, particularly when these are due to intoxication with
central depressant drugs (alcohol,
hypnotics, narcotics). It is contraindicated in severely depressed
patients, in the presence of blood
dyscrasias, liver disease, renal insufficiency, pheochromocytoma, or
in patients with severe
cardiovascular disorders or a history of hypersensitivity to
phenothiazine derivative